ADAMTS13-CONTAINING COMPOSITIONS HAVING THROMBOLYTIC ACTIVITY
This invention relates to a pharmaceutical composition having thrombolytic activity comprising ADAMTS13, and to methods for treating or preventing a disorder associated with the formation and/or the presence of one or more thrombus and to methods of disintegrating one or more thrombus in a patient in need thereof. Furthermore, the invention relates to the use of a pharmaceutically effective amount of ADAMTS13 for the preparation of a pharmaceutical composition for treating or preventing a disorder associated with the formation or the presence of one or more thrombus and for disintegrating one or more thrombus in a patient in need thereof
1 . A pharmaceutical composition having thrombolytic activity, comprising a pharmaceutically effective amount of ADAMTS13 or a biologically active derivative thereof.
2 . The pharmaceutical composition according to claim 1 , wherein ADAMTS13 is recombinant human ADAMTS13 or a biologically active derivative thereof.
3 . The pharmaceutical composition according to claim 1 , wherein the biologically active derivative is a chimeric molecule comprising ADAMTS 13 or a biologically active derivative thereof and Ig or a biologically active derivative thereof.
4 . A method of treating or preventing a disorder associated with the formation and/or the presence of one or more thrombus, comprising the step of administering a composition according to claim 1 to a patient.
5 . A method according to claim 4 , wherein the disorder is selected from the group consisting of hereditary thrombotic thrombocytopenic purpura (TTP), acquired TTP, arterial thrombosis, acute myocardial infarction (AMI), stroke, sepsis, disseminated intravascular coagulation (DIC), and venous thrombosis, such as e.g. deep vein thrombosis or pulmonary embolism.
6 . A method of disintegrating one or more thrombus in a patient in need thereof, comprising the step of administering a composition according to claim 1 to said patient.
7 . The method of claim 4 , wherein the pharmaceutically effective amount of ADAMTS13 or a biologically active derivative thereof ranges from 0.1 to 20 mg/kg body weight.